Neocannbio

Developer of cannabinoid ingredients and natural products for pharmaceutical applications

placeSeoul, Seoul, South Korea calendar_todayFounded 2021 groups8 employees language neocannbio.com

Registered entities

Innovation

13 patent families (1 granted) — focus: Human necessities, Chemistry & metallurgy, Physics & computing; filing pace accelerating. Cited 35 times.

YearFilings
20232
20249
20252
20262

Investor mix

18 investors on record; lead investors include QUAD, Bilanx, Donghoon Investment, Prologue.

Investor typeCountShare
Venture capital422%
Other / undisclosed1478%
Coming soon